IBRX — ImmunityBio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1326110 ·
Last close
$9.91
Market Cap
$10.50B
52W High
$12.43
52W Low
$1.95
ADV30
12,052,510
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 51,240,000 | 50,942,000 | -61,697,000 | -230,378,000 | 628,504,000 | 75,670,000 | 1,674,265,000 |
| Mar 2026 | 44,206,000 | 43,968,000 | -69,791,000 | -632,782,000 | 646,637,000 | 205,194,000 | 1,515,763,000 |
| Dec 2025 | 38,285,000 | 37,903,000 | -64,683,000 | -61,944,000 | 501,898,000 | 88,334,000 | 1,001,472,000 |
| Sep 2025 | 32,061,000 | 31,884,000 | -55,630,000 | -67,253,000 | 518,987,000 | 60,241,000 | 1,042,397,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-281,138,000
Investing CF
$-276,907,000
Financing CF
$496,782,000
CapEx
$-7,376,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.97
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,589,806,000
Inventory
$1,940,000
Receivables
$53,499,000
ST Investments
$281,701,000
EBIT TTM
$-878,096,000
Pretax Income TTM
$-992,580,000
Interest Exp TTM
$114,484,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$165,792,000
EBITDA
$-235,298,000
Free Cash Flow
$-186,564,128
Enterprise Value
$9,255,202,816
Total Cash
$357,371,008
Total Debt
$1,228,401,024
Shares Out
1,059,836,273
Trailing EPS
$-0.95
Book Value
$-0.99
ROE
—
ROA
-30.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 113,288,000 | -256,027,000 | -351,398,000 | 501,898,000 | 1,001,472,000 | -500,469,000 | -304,936,000 |
| Dec 2024 | 14,745,000 | -344,182,000 | -413,564,000 | 382,933,000 | 871,062,000 | -489,098,000 | -391,236,000 |
| Dec 2023 | 622,000 | -361,364,000 | -583,196,000 | 504,452,000 | 1,090,389,000 | -586,987,000 | -366,757,000 |
| Dec 2022 | 240,000 | -350,617,000 | -416,567,000 | 362,356,000 | 812,176,000 | -447,327,000 | -337,509,000 |
TTM Snapshot
Revenues TTM
$140,977,000
NetIncome TTM
$-854,534,000
OpCashFlow TTM
—
Assets (Latest)
$646,637,000
Forward EPS
$-0.13
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TWST | Twist Bioscience Corp | $10.08B | $152.05 | — |
| TECH | BIO-TECHNE Corp | $11.36B | $72.45 | — |
| KRYS | Krystal Biotech, Inc. | $9.69B | $327.30 | — |
| PCVX | Vaxcyte, Inc. | $9.67B | $65.01 | — |
| RGEN | REPLIGEN CORP | $9.25B | $163.84 | — |
News headlines (Yahoo Finance, 1h cache)
ImmunityBio (IBRX) Could Be 33% Undervalued Following Its Ottawa Symposium Update
2026-10-08 09:07 · Yahoo
IBRX Stock Logs Best Week In Over 7 Months: Retail Eyes Anktiva Boost From Trump’s Cancer Panel Pick
2026-10-05 02:13 · Yahoo
SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
2026-10-02 07:02 · Yahoo
IBRX Breaks Above This Key Resistance — Stock On Track To Record Best Single-Day Gains In 6 Months
2026-09-30 16:37 · Yahoo
A $5.8B Cancer Market Opportunity Is Emerging — Why GA-Courtenay Favors ImmunityBio (IBRX)
2026-09-30 12:28 · Yahoo
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
2026-09-30 03:47 · Yahoo
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%
2026-09-23 00:26 · Yahoo
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode
2026-09-21 06:49 · Yahoo
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
2026-09-18 07:41 · Yahoo
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
2026-09-15 04:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.